Effect of Serum Vitamin D Levels on Cardiovascular Mortality and Cardiovascular Disease Risk

Aaron S. Bennion  
*Brigham Young University - Provo*, dblaron.bennion@gmail.com

Karlen E. Luthy  
*Brigham Young University - Provo*, beth-luthy@byu.edu

Donna S. Freeborn  
*Brigham Young University - Provo*, Donna_Freeborn@byu.edu

Renea L. Beckstrand  
*Brigham Young University - Provo*, renea@byu.edu

The College of Nursing showcases some of our best evidence based scholarly papers from graduate students in the Family Nurse Practitioner Program. The papers address relevant clinical problems for advance practice nurses and are based on the best evidence available. Using a systematic approach students critically analyze and synthesize the research studies to determine the strength of the evidence regarding the clinical problem. Based on the findings, recommendations are made for clinical practice. The papers are published in professional journals and presented at professional meetings.

BYU ScholarsArchive Citation

Bennion, Aaron S.; Luthy, Karlen E.; Freeborn, Donna S.; and Beckstrand, Renea L., "Effect of Serum Vitamin D Levels on Cardiovascular Mortality and Cardiovascular Disease Risk" (2012). *Student Works*. 122.  
https://scholarsarchive.byu.edu/studentpub/122

This Master's Project is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Student Works by an authorized administrator of BYU ScholarsArchive. For more information, please contact scholarsarchive@byu.edu, ellen_amatangelo@byu.edu.
Effect of Serum Vitamin D Levels on Cardiovascular Mortality
and Cardiovascular Disease Risk

Aaron Bennion
Graduate Student, FNP Program

Karlen E. Luthy, DNP, FNP-c
Assistant Professor

Donna S. Freeborn, PhD, RN, FNP-c
Assistant Professor

Renea L. Beckstrand, PhD, RN, CCRN, CNE
Professor (Effective 8/12)

College of Nursing
Brigham Young University

Corresponding Author: Renea L. Beckstrand
P.O. Box 25432, 422 SWKT
Provo, UT 84602
801 422-3873
(fax) 801 422-0538
renea@byu.edu

Word Count: 4,217
Effect of Serum Vitamin D Levels on Cardiovascular Mortality and Cardiovascular Disease Risk

Abstract

Vitamin D deficiency is prevalent across all geographic areas, age groups, and seasons and is increasing in incidence. Vitamin D receptors have been found to be present in almost every body cell and tissue. Clinical research has alluded to a preventive effect of vitamin D supplementation on cardiovascular disorders such as myocardial infarction, hypertension, and dyslipidemia. Furthermore, a low serum vitamin D level has been associated with an increased risk for cardiovascular disease. This paper examines the association between serum vitamin D levels and cardiovascular disease mortality and risk.

Key words: Serum vitamin D, cardiovascular mortality, and cardiovascular disease risk.
Effect of Serum Vitamin D Levels on Cardiovascular Mortality
and Cardiovascular Disease Risk

Vitamin D is a secosteroid derived from diet or ultraviolet (UV)-B radiation in the epidermis. Dietary sources rich in vitamin D include egg yolks and animal fat (cholecalciferol or vitamin 25(OH)D₃) and green vegetables (ergocalciferol or vitamin 25(OH)D₂). Vitamin D receptors have been found to be present in almost every body cell and tissue. Plasma or serum 25(OH)D is the most stable and abundant vitamin D metabolite in the bloodstream and is, therefore, the best measure of vitamin D status, achieved through either sunlight or diet.

Vitamin D deficiency is prevalent across all geographic areas, age groups, and seasons and is increasing in incidence. Risk factors for vitamin D deficiency include obesity, decreased exposure to sunlight, decreased cutaneous synthesis related to age, low dietary intake, and high degree of skin pigmentation. Table 1 reports other behaviors and conditions affecting risk for vitamin D deficiency.

There is no consensus among experts on optimum serum 25(OH)D level. Thus, recommendations regarding serum 25(OH)D are varied, depending on the reference. For most populations, the optimal range for serum 25(OH)D levels is at least 30 – 32 ng/mL (75 – 80 nmol/mL). However, Bischoff-Ferrari reports that serum 25(OH)D levels of 30 – 40 ng/mL (75 – 100 nmol/L) have been demonstrated to provide optimal benefits without an associated increase in health risk. An even higher range, 40 – 50 ng/mL (100 – 125), has also been reported as the ideal goal for serum 25(OH)D levels.

It has been speculated that more than 75% of Americans have abnormally low levels of serum 25(OH)D. Data from the National Health and Nutrition Examination
Survey showed that 75% to 80% of subjects had serum 25(OH)D levels of <30 ng/mL (<75 nmol/L), numbers that experts unanimously agree are too low.\textsuperscript{1,5} The Institute of Medicine, however, believes a 75% approximation of vitamin D deficiency in Americans to be an overestimation. The Institute of Medicine reports that 25% of Americans have inadequate levels of serum 25(OH)D and that only 8% of Americans are at risk for deficiency.\textsuperscript{3} The Institute of Medicine also estimates that 1% of Americans have serum 25(OH)D levels that are too high and, consequently, possibly causing harm.\textsuperscript{3} Serum 25(OH)D levels ranging from deficient to intoxicated are classified in Table 2.

Some reports of vitamin D supplementation note no adverse or toxic effects with dosages as high as 10,000 IU/day.\textsuperscript{8-9} However, when dosages are equal to or greater than 50,000 IU/day, over weeks to months, toxic adverse events such as hypercalcemia leading to hypercalciuria and eventual renal and cardiovascular failure result in death from vitamin D toxicity.\textsuperscript{8} Despite acknowledging no adverse events with dosages as high as 10,000 IU/day,\textsuperscript{8} the Institute of Medicine currently recommends more conservative daily allowances (see Table 3).\textsuperscript{10}

**Cardiovascular Effects**

The effect of vitamin D supplementation on bone health is well documented.\textsuperscript{11-12} Heart disease is currently the leading cause of death for both men and women, with a $316.4 billion estimated annual cost in the United States alone.\textsuperscript{13} Emerging evidence suggests that optimal serum 25(OH)D levels may also improve cardiovascular outcomes, such as reducing hypertension, improving lipid management, and reducing incidence of myocardial infarction and cardiovascular mortality.\textsuperscript{14-19} Several observational studies have linked vitamin D deficiency with a higher incidence of
cardiovascular disease in the general population.\textsuperscript{14-15, 20} Epidemiological studies note a proportional increase in the rate of both coronary heart disease and hypertension in those living farther away from the equator.\textsuperscript{3} This increased rate of cardiovascular disease in locations farther away from the equator could potentially suggest an association with lower serum vitamin D levels.\textsuperscript{3}

Vitamin D regulates many genes either directly or indirectly including those involved in the proliferation of cardiac muscle cells, vascular smooth muscle, macrophages and lymphocytes.\textsuperscript{3} Vitamin D is also postulated to improve cardiovascular health through multiple pathways, including inhibition of vascular smooth muscle proliferation, increased regulation of inflammatory mediators, suppression of vascular calcification, and improved modulation of the renin-angiotensin system.\textsuperscript{14, 21} This article examines the association between serum 25(OH)D levels and cardiovascular disease mortality and cardiovascular disease risk.

**Methods**

An electronic search was conducted to identify studies from 2006 to 2012 in the following databases: CINAHL, Medline, PsycInfo, and the Cochrane library. Search terms included vitamin D, cardiovascular, cardiac, myocardial infarction, hypertension, and lipids. The search was limited to English, peer-reviewed studies. Utilizing these criteria, 54 articles were initially identified. Studies were further limited to clinical trials, meta-analyses, and epidemiological studies. Studies were excluded if animals were used as subjects. References from articles were reviewed for additional relevant studies and reviews; multiple resources were identified, bringing the total number of articles for inclusion to 37.
Results

Cardiovascular Mortality

Without Supplementation

A prospective cohort study of 3,258 patients referred for elective coronary angiography and followed for 7 years demonstrated an independent association between low serum 25(OH)D and cardiovascular mortality (HR 2.22, 95% CI 1.57-3.13 for the lowest serum 25(OH)D quartile [median 7.3 ng/mL] when compared with patients in the highest serum 25(OH)D quartile [median 28.4 ng/mL]). However, the researchers noted that it had yet to be proven by interventional trial that a causal relationship exists between vitamin D and mortality.

In another prospective study, Ginde and colleagues demonstrated an independent, inverse association between baseline serum 25(OH)D levels and cardiovascular disease mortality and all-cause mortality in the Third National Health and Nutrition Examination Survey. Compared with subjects with serum 25(OH)D > 40 ng/mL, the adjusted hazard ratio of all-cause mortality for subjects with serum 25(OH)D < 10 ng/mL was 1.83 (95% CI 1.14 - 2.94). There was an even stronger association in subjects with lower serum 25(OH)D levels (< 10 ng/mL) when compared to subjects with higher serum 25(OH)D levels (> 40 ng/mL) for cardiovascular disease mortality (adjusted HR = 2.36; 95% CI = 1.17 - 4.75).

Researchers examining 2,312 healthy subjects from the Cardiovascular Health Study noted at the 14-year follow-up a greater incidence of sudden cardiac death in subjects with lower serum vitamin D levels. Researchers documented two sudden cardiac death (SCD) events per 1,000 in subjects with serum vitamin D levels ≥ 20
ng/mL and four events per 1,000 in subjects with serum 25 (OH)D levels < 20 ng/mL. While these researchers also examined parathyroid hormone (PTH) levels, they concluded that the combination of lower serum 25(OH)D levels and higher PTH levels were associated with an increased risk of SCD in adults presenting without cardiovascular disease as baseline.

**With Vitamin D Supplementation**

In a meta-analysis of randomized controlled trials (RCTs), Autier and Gandini examined the risk of dying from any cause in subjects who participated in RCTs testing the effect of vitamin D supplementation on any health condition. Subjects were followed for a mean of 5.7 years. Daily doses of vitamin D supplementation ranged from 300 to 2000 IU, with a trial size-adjusted mean dose of 528 IU/day. They identified a modest, but statistically significant reduction in the relative risk of all-cause mortality (RR = 0.92, 95% CI = 0.87-0.99) with vitamin D supplementation. However, they noted their meta-analysis was not powered sufficiently to identify cause of mortality or variation in specific populations; nor could it account for baseline vitamin D status.

In an investigation to determine whether vitamin D or calcium supplementation affected vascular disease mortality or cancer in the elderly, 5,292 subjects over the age of 70 years were studied. Participants were randomly assigned to one of four groups: vitamin D₃ 800 IU, calcium 1000 mg, both, or placebo. These groups were supplemented for 24 – 62 months, and then received follow-up 3 years post-intervention. There was no difference in vascular disease mortality (HR 1.07; 95% CI = 0.92-1.24). However, in post hoc analysis, adjusting for compliance with fewer participants, trends for reduced mortality with vitamin D supplementation were
accentuated, but still remained non-significant. Vitamin D supplementation did not appear to affect mortality or vascular disease in this long-term follow-up study. The researchers noted that they chose a three-year post intervention follow-up because the effects of calcium supplementation tend to diminish two years after stopping supplementation.25

In the Cardiovascular Health Study, 1,018 subjects were studied over a median of 11 years.26 Researchers discovered that serum 25(OH)D levels of 20 ng/mL or less were associated with an increased risk for clinical disease events. They also determined season-specific serum 25(OH)D concentrations for winter, spring, summer, and fall, were respectively 17, 20, 24, and 22 ng/mL.26 Because of these results the authors postulate that using season-specific targets for serum 25(OH)D levels may be better than using standard normal ranges when evaluating risks to health.26

Myocardial Infarction

The modest decrease in all-cause mortality reported by Autier and Gandini24 could be due to vitamin D’s effects on vasculature. Vitamin D has been purported to affect vascular smooth muscle proliferation, inflammation, vascular calcification, and blood pressure, all of which affect the risk of cardiovascular disease and myocardial infarction.21

However, the only RCT identified examining the effect of vitamin D supplementation on myocardial infarction failed to find a significant effect of supplementing calcium carbonate 1000 mg and vitamin D₃ 400 IU daily over seven years.27 This RCT was associated with the Women’s Health Initiative, in which the dose of vitamin D was likely too low to have an effect, adherence was poor, and concurrent
calcium and vitamin D supplementation was allowed, thus impairing the ability of researchers to identify any treatment effect.\textsuperscript{27}

Despite inconclusive results from the Women’s Health Initiative, observational data seems to be compelling for an effect of serum vitamin D and myocardial infarction risk. In a prospective study of 18,225 men with no known coronary disease, Giovannucci et al.\textsuperscript{14} observed that subjects with serum 25(OH)D levels < 15 ng/ml are at an increased risk for myocardial infarction compared to those with sufficient serum 25(OH)D levels (> 30 ng/mL) (RR 2.09, 95% CI 1.53-3.84). This two-fold increase in risk of myocardial infarction was present even after controlling for factors known to be associated with coronary artery disease, including family history of myocardial infarction, history of diabetes mellitus or hypertension, dyslipidemia, body mass index, and physical activity.\textsuperscript{14}

In another observational study, Lee et al.\textsuperscript{16} found that among a multicenter myocardial infarction registry, 75% of patients were vitamin D deficient (serum 25(OH)D ≤ 20 ng/mL); researchers reported 96% of myocardial infarction patients presented with abnormally low serum 25(OH)D levels (< 30 ng/ml). Interestingly, this report far exceeds the estimated 25% of the American population with serum 25(OH)D levels < 30 ng/mL reported by the Institute of Medicine.\textsuperscript{3}

**Hypertension**

Epidemiological data from National Health and Nutrition Examination Survey links vitamin D deficiency with hypertension.\textsuperscript{18-19} Several interventional studies have included blood pressure as a secondary end point with mixed results.\textsuperscript{27-30} No significant change in blood pressure was reported by Maki et al.\textsuperscript{28} who primarily examined the
effect of 1200 IU vitamin D/day on serum lipids, or by Zitterman et al.\textsuperscript{29} who studied the
effect of 3332 IU vitamin D/day on several cardiovascular risk factors. Although Jorde et
al.\textsuperscript{30} documented a slight but statistically significant increase in diastolic blood pressure
with vitamin D supplementation as compared to the placebo group, Hsia and
colleagues\textsuperscript{27} reported a slight but significant decrease in diastolic blood pressure and
increase in systolic blood pressure in the treatment group during the first two years of
follow-up in the Women’s Health Initiative randomized controlled trial on bone fracture;
these differences in groups became insignificant, however, through later years of follow-
up.

In a meta-analysis examining the effect of vitamin D supplementation on blood
pressure, Witham et al.\textsuperscript{31} found weak evidence for a positive effect. No reduction in
blood pressure was seen in those who were normotensive at baseline. Among those
hypertensive at baseline, researchers reported no significant reduction in systolic blood
pressure (-3.6 mmHg, 95% CI -8 to 0.7) and a small, but statistically significant
reduction in diastolic blood pressure (-3.1 mmHg, 95% CI -5.5 to -0.6).\textsuperscript{31} Significant
heterogeneity was present between studies included in Witham’s\textsuperscript{31} meta-analysis, in
addition to multiple self-reported methodological weaknesses; researchers disclosed
that results should be treated with considerable caution.

Even if no true effect of vitamin D supplementation on blood pressure exists,
there could still be beneficial outcomes from supplementation among hypertensive
patients. Wang et al.\textsuperscript{20} examined baseline serum 25(OH)D levels and the associated
risk of cardiovascular events in 1,739 Framingham Offspring Study participants without
prior known cardiovascular disease. Cardiovascular disease events included myocardial
Effect of Serum Vitamin D

Infarction, coronary insufficiency, angina, stroke, transient ischemic attack, peripheral claudication, or heart failure. Individuals with serum 25(OH)D < 15 ng/mL had a multivariable-adjusted hazard ratio 1.62 (95% CI 1.11 to 2.36, \( P = 0.01 \)) for incident cardiovascular events compared with serum 25(OH)D > 15 ng/mL.\(^{20}\) The effect was evident in those with hypertension (HR 2.13, 95% CI 1.30 to 3.48, \( P = 0.003 \)) but not in those without hypertension (HR 1.04, 95% CI 0.55 to 1.96, \( P = 0.90 \)), suggesting that vitamin D deficiency somehow exacerbates the harmful effects of hypertension.\(^{20}\)

**Serum Lipids**

The increased rate of cardiovascular mortality among vitamin D deficient subjects demonstrated in prospective studies may be explained, partially, by the theorized beneficial effects of vitamin D on serum lipids.\(^{15,22,24}\) In a cross-sectional analysis, Maki et al.\(^{17}\) observed that each additional 10 ng/mL of serum 25(OH)D corresponded to a 4.2 mg/dl increase in high density lipoprotein cholesterol (\( P < 0.01 \)). However, in a randomized controlled trial, supplementation with Vitamin D\(_3\) at a dose of 1200 IU/day over eight weeks failed to affect cardiovascular disease markers such as total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and triglycerides in subjects with elevated waist circumference.\(^{28}\) These results came while documenting a mean increase of 4.9 ± 1.2 ng/mL in serum 25(OH)D levels in the treatment group versus 0.5 ± 1.0 in the placebo group (\( P = 0.003 \)).\(^{28}\) In a study of 1,529 postmenopausal women, no significant difference was noted on serum lipids from supplementation with 1 gm calcium carbonate and 400 IU Vitamin D\(_3\)/day over five years.\(^{32}\) A Norwegian study raised serum 25(OH)D levels 31.8 ± 12.5 ng/ml from a baseline 23.2 ± 8.5 ng/mL with 40,000
IU Vitamin D3 weekly over 12 months ($P < 0.001$ versus the placebo group), yet failed to demonstrate an effect on serum lipids. However, serum lipids were secondary endpoints in this study; researchers disclosed the study was not designed nor powered to detect such effects.

In contrast to these equivocal results of Vitamin D supplementation, Zitterman et al. demonstrated a reduction in triglycerides (-13.5% versus +3% with placebo, $P < 0.001$) while noting an unexpected increase in low density lipoprotein cholesterol (+5.4% versus -2.5%, $P < 0.001$); high density lipoprotein cholesterol appeared unaffected. All subjects in this study were overweight and significantly vitamin D deficient (mean baseline serum 25(OH)D = 12 ng/ml); they were supplemented at a dose of 3332 IU vitamin D3 daily or with placebo for 12 months while participating in a weight reduction program. Reporting similar results, Salehpour and colleagues also demonstrated in randomized controlled trial RCT an increased low density lipoprotein cholesterol and total cholesterol while documenting an improved high density lipoprotein cholesterol by supplementing 77 healthy premenopausal overweight and obese women with 1000 UI vitamin D3 daily for 12 weeks.

In a retrospective chart review, significant reductions were reported in total cholesterol, low density lipoprotein cholesterol, and triglycerides (-48.6 mg/dl, -45.5 mg/dl, -44.7 mg/dl, respectively; $P < 0.001$), by use of statin therapy, niacin and/or omega-3 fatty acid supplementation, and vitamin D supplementation titrated to achieve serum 25(OH)D levels 50 – 60 ng/mL. It should be noted that this study had several reported methodological weaknesses, including an all-white, highly motivated population and the lack of a control group. Given the design of the study, it is not
possible to determine which variables were responsible for observed outcomes, and results should be interpreted with caution.\textsuperscript{34}

\section*{Discussion}

While evidence for epidemiological and clinical studies tend to support an association between vitamin D deficiency and the incidence of cardiovascular disease, caution must be taken due to the number of potential confounding variables that are not possible to control.\textsuperscript{35} Observational data is compelling, but not adequate for establishing causation. Because interactions between vitamin D, calcium, and parathyroid hormone are complex, separating the effects distinct to vitamin D in clinical trial can be difficult.\textsuperscript{35} Furthermore, Ullah and colleagues\textsuperscript{35} note statistical significance in a study report does not prove that one factor has caused another; these two factors may be closely related to a third.\textsuperscript{35} Since there is increasing evidence linking vitamin D deficiency and cardiovascular disease, treating hypovitaminosis D in patients at risk could be prudent.\textsuperscript{35} Further, a recent Endocrine Society’s scientific statement notes that research is inconsistent on the associated benefits of supplemental vitamin D outside of bone health effects.\textsuperscript{36}

\section*{Recommendations for Future Research}

Few randomized controlled trials to date have used vitamin D doses that would raise serum 25(OH)D levels above 30 ng/mL.\textsuperscript{28-30} As such, appropriate hope remains about potential cardiovascular benefits of vitamin D supplementation. Randomized controlled trials that primarily evaluate the effects vitamin D supplementation doses in the range of 2000-5000 IU/day on cardiovascular health outcomes are needed.\textsuperscript{12} Large
randomized controlled trials are needed along with dose-response data to determine the effects of vitamin D on heart disease and hypertension.\textsuperscript{37}

\textbf{Current Recommendations}

The Institute of Medicine currently recommends a dietary intake of 600 IU/day of vitamin D for all adults 18 to 70 years and 800 IU/day for adults greater than 70 years with an upper level intake of 4000 IU/day for all adults.\textsuperscript{10} Holick et al.\textsuperscript{12} proposes supplementation with at least 1000 IU of vitamin D per day to guarantee vitamin D sufficiency in normal circumstances. Screening for vitamin D deficiency should only be performed for those individuals at risk for deficiency (see Table 1).\textsuperscript{12} At present, the Endocrine Society recommends that all adults who are vitamin D deficient be treated with 50000 IU of vitamin D\textsubscript{2} or vitamin D\textsubscript{3} once a week (or the equivalent dose of 6000 IU/day) for 8 weeks to achieve rapid repletion, followed by a maintenance dose of 1500-2000 IU/day.\textsuperscript{12} Supplementation of vitamin D doses at least two to three times larger may be needed for obese individuals (body mass index > 30 kg/m\textsuperscript{2}) (body fat sequesters the fat-soluble vitamin) and individuals on anticonvulsant medications, glucocorticoids, antifungals (such as ketoconazole), or medications for AIDS (these medications increase the catabolism of 25(OH)D).\textsuperscript{12}

\textbf{Conclusion}

In conclusion, there are a large number of observational studies demonstrating an association between vitamin D deficiency and multiple adverse cardiovascular outcomes, including dyslipidemia, hypertension, myocardial infarction and cardiovascular disease mortality. Yet observational data does not establish causation. Though lacking sufficient evidence for the benefits of vitamin D supplementation in
Effect of Serum Vitamin D

reducing risk of cardiovascular disease mortality, the literature does give reassurance that long-term supplementation with ordinary doses of vitamin D does not seem to be associated with an adverse effect. However, it is premature to prescribe vitamin D supplementation beyond recommended daily needs for preventing cardiovascular disease or death.

Acknowledgements

Brigham Young University College of Nursing was the location where this work was completed.

Author Contribution/Roles

The first rough draft of this article was written by Aaron Bennion. Dr. Beckstrand was the senior investigator who acted as mentor and also contributed to this work. Dr. Luthy and Dr. Freeborn contributed to the editing and clarification in writing for the article.

Declaration of Conflicting Interests

None. There are no commercial, financial, or other associations for this article.

Financial Disclosure/Funding

This research and its authorship received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
References


### Table 1. Behaviors and Conditions Affecting Risk for Vitamin D Deficiency

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunscreen use</td>
<td></td>
</tr>
<tr>
<td>Obesity and physical inactivity</td>
<td></td>
</tr>
<tr>
<td>Aging</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
</tr>
<tr>
<td>Malabsorption syndromes</td>
<td></td>
</tr>
<tr>
<td>Cystic fibrosis</td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td></td>
</tr>
<tr>
<td>Crohn’s disease</td>
<td></td>
</tr>
<tr>
<td>Bariatric surgery</td>
<td></td>
</tr>
<tr>
<td>Nephrotic syndrome</td>
<td></td>
</tr>
<tr>
<td>Renal Disease</td>
<td></td>
</tr>
<tr>
<td>Medications</td>
<td></td>
</tr>
<tr>
<td>Antiseizure medications</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td></td>
</tr>
<tr>
<td>AIDS medications</td>
<td></td>
</tr>
<tr>
<td>Antifungals</td>
<td></td>
</tr>
<tr>
<td>Cholestyramine</td>
<td></td>
</tr>
<tr>
<td>Chronic granuloma forming disorders</td>
<td></td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td></td>
</tr>
<tr>
<td>Tuberculosis</td>
<td></td>
</tr>
<tr>
<td>Histoplasmosis</td>
<td></td>
</tr>
<tr>
<td>Primary hyperparathyroidism</td>
<td></td>
</tr>
<tr>
<td>Pregnancy/lactation</td>
<td></td>
</tr>
</tbody>
</table>

Adapted from Lavie et al.,$^3$ and Holick et al.$^{11,12}$
Table 2. Serum 25 (OH)D Levels Ranging from Deficiency to Intoxication

<table>
<thead>
<tr>
<th>Status</th>
<th>Serum 25(OH)D level*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deficient</td>
<td>≤ 20 ng/mL</td>
</tr>
<tr>
<td>Insufficient</td>
<td>&gt; 20 to &lt; 30 ng/mL</td>
</tr>
<tr>
<td>Sufficient/Optimal</td>
<td>≥ 30 to &lt; 40 ng/mL</td>
</tr>
<tr>
<td>Ideal</td>
<td>≥ 40 to ≤ 50 ng/mL</td>
</tr>
<tr>
<td>Intoxicated</td>
<td>&gt; 150 ng/mL</td>
</tr>
</tbody>
</table>

* To convert from ng/mL to nmol/L, multiply by 2.496.

Adapted from Lavie et al., Holick et al., and Lee et al.
<table>
<thead>
<tr>
<th>Life Stage Group</th>
<th>Estimated Average Requirement (IU/day)</th>
<th>Recommended Dietary Allowance (IU/day)</th>
<th>Upper Level Intake (IU/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-3 years old</td>
<td>400</td>
<td>600</td>
<td>2,500</td>
</tr>
<tr>
<td>4-8 years old</td>
<td>400</td>
<td>600</td>
<td>3,000</td>
</tr>
<tr>
<td>9-70 years old</td>
<td>400</td>
<td>600</td>
<td>4,000</td>
</tr>
<tr>
<td>&gt;70 years old</td>
<td>400</td>
<td>800</td>
<td>4,000</td>
</tr>
<tr>
<td>14-50 years old, pregnant/lactating</td>
<td>400</td>
<td>600</td>
<td>4,000</td>
</tr>
</tbody>
</table>

Adapted from the Institute of Medicine Dietary Reference Intakes for Vitamin D.